title: Atrial natriuretic factor in essential hypertension and adrenal disorders.
abstract: Patients with untreated essential hypertension had significantly higher plasma atrial natriuretic factor (ANF) levels (92.9 +/- 12.9 pg/ml, mean +/- SE) than those of age-matched controls (37.8 +/- 6.0 pg/ml; p less than 0.01). Plasma ANF levels in essential hypertensive patients showed a significant positive correlation with mean arterial pressure (MAP; r = 0.46, p less than 0.05) and an inverse correlation with plasma renin activity (PRA; r = -0.43, p less than 0.05). Plasma ANF levels after medication showed significant correlation with the decrease in MAP (r = 0.565, p less than 0.05). Patients with primary aldosteronism had significantly higher plasma ANF levels (122.4 +/- 30.2 pg/ml, n = 8) than those of controls (p less than 0.05). The levels returned to normal after extirpation of adrenal tumors. The response of plasma ANF levels in patients with primary aldosteronism to volume expansion with infusion of 2 L of physiological saline in 2 hours was greater than in controls. Such exaggerated response disappeared after surgical treatment. Infusion of angiotensin II (Ang II; 20 ng/kg/min) or norepinephrine (200 ng/kg/min) for 30 minutes to normal volunteers (n = 5) resulted in a rise in MAP (24.9 +/- 3.3 and 15.8 +/- 4.4 mm Hg, respectively) and a twofold increase in plasma ANF level. Infusion of the Ang II antagonist [Sar1, Ile8]Ang II (600 ng/kg/min) for 30 minutes, resulted in a rise in MAP (18.8 +/- 2.1 mm Hg) and more than a twofold increase in plasma ANF level in patients with essential hypertension (n = 6).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Kyoto University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Sugawara
authors.forename: K
authors.initials: K
authors.lastname: Nakao
authors.forename: T
authors.initials: T
authors.lastname: Kono
authors.forename: N
authors.initials: N
authors.lastname: Morii
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Itoh
authors.forename: S
authors.initials: S
authors.lastname: Shiono
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Mukoyama
authors.forename: H
authors.initials: H
authors.lastname: Arai
mesh_terms: D000307:Adrenal Gland Diseases / Q000097:blood* / Q000503:physiopathology; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001794:Blood Pressure; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000503:physiopathology; D006973:Hypertension / Q000097:blood* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine; D012083:Renin / Q000097:blood; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D012083:Renin; D009638:Norepinephrine